Announcements

NOTE: Since August 24th, the Funds’ third-party administrator has been experiencing technical issues with its fund accounting software impacting its ability to calculate NAV for its ETF clients, including the Funds. As a result, the NAV we are presenting here for the Funds is the closing indicative NAV of the Funds, which represents the best available information at this time. Upon correction of the problem, these indicative NAVs will be compared to actual values, adjustments will be made and shareholders will be notified as required. Please contact the Virtus ETF Advisers help desk at 888-383-0553 for more information.

Following rebalance, BBC and BBP funds offer increased diversity of holdings

 

The BioShares ETF team will visit the Nasdaq MarketSite in Times Square to celebrate the listing of the BBC and BBP ETFs and ring the Opening Bell

BioShares Launches Two New Biotechnology ETFs (Nasdaq: BBC, BBP) BioShares Biotechnology Funds give investors unique and selective exposure to the dynamic, high-growth biotechnology sector New York, December 17, 2014 — LifeSci Index Partners, LLC (“LSIP”), a New York City-based investment advisor and index provider, today launched the BioShares™ Biotechnology Clinical Trials Fund (Nasdaq: BBC) and the BioShares™ Biotechnology Products Fund (Nasdaq: BBP) (together, “the Funds”).  The Funds are designed by a team of biotechnology investment specialists and allow investors, for the first time, to choose from two distinct groups of stocks that are typically grouped together in other funds – advanced products stage